Finance

Lists
KRRO:NASDAQ
Korro Bio Inc
$10.02
-15.08%
(-1.78) 1D
$10.25
+2.32% (+0.23)
After hours
Closed: Sep 18, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KRRO...
Open
$11.71
High
$11.94
Low
$9.50
Mkt. cap
147.55M
Avg. vol.
118.72K
Volume
763.40K
52-wk high
$55.89
52-wk low
$5.20
EPS
-$10.00
Beta
3.09
Shares outstanding
14.73M
No. of employees
57
Open
$11.71
High
$11.94
Low
$9.50
Mkt. cap
147.55M
Avg. vol.
118.72K
Volume
763.40K
52-wk high
$55.89
52-wk low
$5.20
EPS
-$10.00
Beta
3.09
Shares outstanding
14.73M
No. of employees
57
News stories
From web sources and news partners
About Korro Bio Inc
CEO-
Employees57
Founded2014
Headquarters-
SectorBiotechnology
Websitekorrobio.com
Analyst ratings
Based on 9 analysts giving stock ratings to KRRO in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for KRRO in the last 3 months.
Highest
Current $10.02
$30.00 (+199.40%)
Average
$19.00 (+89.62%)
Lowest
$10.00 (-0.20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
$21.00
+109.6%
09/09/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$15.00
+49.7%
08/21/2026
Luca Issi
RBC Capital
Hold
Maintained
$10.00
-0.2%
08/07/2026
Unknown Analyst
LifeSci Capital
Buy
Maintained
$21.00
+109.6%
08/07/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$30.00
+199.4%
08/07/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$22.00
+119.6%
08/06/2026
William Maughan
Clear Street
Buy
Maintained
$18.00
+79.6%
08/07/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$15.00
+49.7%
08/06/2026
Catherine Novack
JonesTrading
Buy
Upgraded
$23.00
+129.5%
05/08/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$22.00
+119.6%
03/13/2026
Ryan Deschner
Raymond James
Buy
Upgraded
$23.00
+129.5%
03/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.09M
1.29M
-
-
Cost of goods sold
11.26M
8.60M
11.53M
11.63M
Cost of revenue
11.26M
8.60M
11.53M
11.63M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.06M
8.58M
8.91M
8.48M
Operating expense
9.06M
8.58M
8.91M
8.48M
Total operating expenses
20.33M
17.18M
20.44M
20.11M
Operating income
-19.24M
-15.88M
-20.44M
-20.11M
Other non operating income
1.18M
990.00K
-
-
EBT including unusual items
-18.06M
-49.41M
-19.53M
-18.81M
EBT excluding unusual items
-18.06M
-14.89M
-19.53M
-18.81M
Income tax expense
-
636.00K
95.00K
108.00K
Effective tax rate
-
-1.29%
-0.49%
-0.57%
Other operating expenses
-
-
-
-
Net income
-18.06M
-50.04M
-19.62M
-18.92M
Net profit margin
-1,656.97%
-3,873.22%
-
-
Earnings per share
-1.92
-1.65
-1.69
-1.07
Interest and investment income
-
-
906.00K
1.30M
Interest expense
-
-
-
-
Net interest expenses
-
-
906.00K
1.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.06M
-15.23M
-20.06M
-19.74M
Gain or loss from assets sale
-
-18.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps